Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review

National MS Society Cognition Work Team

Research output: Contribution to journalReview article

Abstract

Background: The proliferation of computerized neuropsychological assessment devices (CNADs) for screening and monitoring cognitive impairment is increasing exponentially. Previous reviews of computerized tests for multiple sclerosis (MS) were primarily qualitative and did not rigorously compare CNADs on psychometric properties. Objective: We aimed to systematically review the literature on the use of CNADs in MS and identify test batteries and single tests with good evidence for reliability and validity. Method: A search of four major online databases was conducted for publications related to computerized testing and MS. Test–retest reliability and validity coefficients and effect sizes were recorded for each CNAD test, along with administration characteristics. Results: We identified 11 batteries and 33 individual tests from 120 peer-reviewed articles meeting the inclusion criteria. CNADs with the strongest psychometric support include the CogState Brief Battery, Cognitive Drug Research Battery, NeuroTrax, CNS-Vital Signs, and computer-based administrations of the Symbol Digit Modalities Test. Conclusion: We identified several CNADs that are valid to screen for MS-related cognitive impairment, or to supplement full, conventional neuropsychological assessment. The necessity of testing with a technician, and in a controlled clinic/laboratory environment, remains uncertain.

Original languageEnglish (US)
JournalMultiple Sclerosis Journal
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Multiple Sclerosis
Equipment and Supplies
Psychometrics
Reproducibility of Results
Vital Signs
Publications
Databases
Research
Pharmaceutical Preparations
Cognitive Dysfunction

Keywords

  • cognition
  • computerized tests
  • Multiple sclerosis
  • reliability
  • systematic review
  • validity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Computerized neuropsychological assessment devices in multiple sclerosis : A systematic review. / National MS Society Cognition Work Team.

In: Multiple Sclerosis Journal, 01.01.2019.

Research output: Contribution to journalReview article

@article{e83ac241b69d499b9e336059b949f714,
title = "Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review",
abstract = "Background: The proliferation of computerized neuropsychological assessment devices (CNADs) for screening and monitoring cognitive impairment is increasing exponentially. Previous reviews of computerized tests for multiple sclerosis (MS) were primarily qualitative and did not rigorously compare CNADs on psychometric properties. Objective: We aimed to systematically review the literature on the use of CNADs in MS and identify test batteries and single tests with good evidence for reliability and validity. Method: A search of four major online databases was conducted for publications related to computerized testing and MS. Test–retest reliability and validity coefficients and effect sizes were recorded for each CNAD test, along with administration characteristics. Results: We identified 11 batteries and 33 individual tests from 120 peer-reviewed articles meeting the inclusion criteria. CNADs with the strongest psychometric support include the CogState Brief Battery, Cognitive Drug Research Battery, NeuroTrax, CNS-Vital Signs, and computer-based administrations of the Symbol Digit Modalities Test. Conclusion: We identified several CNADs that are valid to screen for MS-related cognitive impairment, or to supplement full, conventional neuropsychological assessment. The necessity of testing with a technician, and in a controlled clinic/laboratory environment, remains uncertain.",
keywords = "cognition, computerized tests, Multiple sclerosis, reliability, systematic review, validity",
author = "{National MS Society Cognition Work Team} and Wojcik, {Curtis M.} and Meghan Beier and Kathleen Costello and John DeLuca and Anthony Feinstein and Yael Goverover and Mark Gudesblatt and Michael Jaworski and Rosalind Kalb and Lori Kostich and LaRocca, {Nicholas G.} and Rodgers, {Jonathan D.} and Benedict, {Ralph H.B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1352458519879094",
language = "English (US)",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Computerized neuropsychological assessment devices in multiple sclerosis

T2 - A systematic review

AU - National MS Society Cognition Work Team

AU - Wojcik, Curtis M.

AU - Beier, Meghan

AU - Costello, Kathleen

AU - DeLuca, John

AU - Feinstein, Anthony

AU - Goverover, Yael

AU - Gudesblatt, Mark

AU - Jaworski, Michael

AU - Kalb, Rosalind

AU - Kostich, Lori

AU - LaRocca, Nicholas G.

AU - Rodgers, Jonathan D.

AU - Benedict, Ralph H.B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The proliferation of computerized neuropsychological assessment devices (CNADs) for screening and monitoring cognitive impairment is increasing exponentially. Previous reviews of computerized tests for multiple sclerosis (MS) were primarily qualitative and did not rigorously compare CNADs on psychometric properties. Objective: We aimed to systematically review the literature on the use of CNADs in MS and identify test batteries and single tests with good evidence for reliability and validity. Method: A search of four major online databases was conducted for publications related to computerized testing and MS. Test–retest reliability and validity coefficients and effect sizes were recorded for each CNAD test, along with administration characteristics. Results: We identified 11 batteries and 33 individual tests from 120 peer-reviewed articles meeting the inclusion criteria. CNADs with the strongest psychometric support include the CogState Brief Battery, Cognitive Drug Research Battery, NeuroTrax, CNS-Vital Signs, and computer-based administrations of the Symbol Digit Modalities Test. Conclusion: We identified several CNADs that are valid to screen for MS-related cognitive impairment, or to supplement full, conventional neuropsychological assessment. The necessity of testing with a technician, and in a controlled clinic/laboratory environment, remains uncertain.

AB - Background: The proliferation of computerized neuropsychological assessment devices (CNADs) for screening and monitoring cognitive impairment is increasing exponentially. Previous reviews of computerized tests for multiple sclerosis (MS) were primarily qualitative and did not rigorously compare CNADs on psychometric properties. Objective: We aimed to systematically review the literature on the use of CNADs in MS and identify test batteries and single tests with good evidence for reliability and validity. Method: A search of four major online databases was conducted for publications related to computerized testing and MS. Test–retest reliability and validity coefficients and effect sizes were recorded for each CNAD test, along with administration characteristics. Results: We identified 11 batteries and 33 individual tests from 120 peer-reviewed articles meeting the inclusion criteria. CNADs with the strongest psychometric support include the CogState Brief Battery, Cognitive Drug Research Battery, NeuroTrax, CNS-Vital Signs, and computer-based administrations of the Symbol Digit Modalities Test. Conclusion: We identified several CNADs that are valid to screen for MS-related cognitive impairment, or to supplement full, conventional neuropsychological assessment. The necessity of testing with a technician, and in a controlled clinic/laboratory environment, remains uncertain.

KW - cognition

KW - computerized tests

KW - Multiple sclerosis

KW - reliability

KW - systematic review

KW - validity

UR - http://www.scopus.com/inward/record.url?scp=85074405382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074405382&partnerID=8YFLogxK

U2 - 10.1177/1352458519879094

DO - 10.1177/1352458519879094

M3 - Review article

C2 - 31637963

AN - SCOPUS:85074405382

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -